Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Amortization of Deferred Charges: 2010-2023

Historic Amortization of Deferred Charges for Lineage Cell Therapeutics (LCTX) over the last 7 years, with Dec 2023 value amounting to $22,000.

  • Lineage Cell Therapeutics' Amortization of Deferred Charges rose 99.91% to -$720 in Q4 2014 from the same period last year, while for Dec 2014 it was -$840,086, marking a year-over-year increase of 8.19%. This contributed to the annual value of $22,000 for FY2023, which is N/A change from last year.
  • As of FY2023, Lineage Cell Therapeutics' Amortization of Deferred Charges stood at $22,000, which was down 78.43% from $102,000 recorded in FY2015.
  • In the past 5 years, Lineage Cell Therapeutics' Amortization of Deferred Charges ranged from a high of $22,000 in FY2023 and a low of $22,000 during FY2023.
  • For the 1-year period, Lineage Cell Therapeutics' Amortization of Deferred Charges averaged around $22,000, with its median value being $22,000 (2023).